Century Therapeutics, Inc. (IPSC) Form 8-K — Aug 12, 2026
Century Therapeutics reported a net loss of $34.6 million for the second quarter of 2026, compared with a $32.5 million net loss a year ago, with R&D expenses of $19.6 million (down from $26.9 million) and G&A expenses of $5.8 million (down from $7.8 million). The quarter included an $11.1 million loss on lease component termination tied to the company's previously announced portfolio prioritization, and no collaboration revenue was recorded in the period. Cash, cash equivalents, and investments stood at $197.2 million as of June 30, 2026, up from $117.1 million at year-end 2025 following an oversubscribed $135 million PIPE earlier in the year.
Key figures
- Revenue
- 0
- Total Assets
- 287006000
- Cash Position
- 197200000
- Cash Runway
- into 1Q 2029
- Cash Dec31 2025
- 117100000
- Net Loss Q2 2025
- 32541000
- Ga Expense Q2 2025
- 7800000
- Ga Expense Q2 2026
- 5800000
- Rnd Expense Q2 2025
- 26900000
- Rnd Expense Q2 2026
- 19600000
- Cnty308 Clinic Entry
- 2026
- Ind Submission CNTY813
- 4Q 2026
- Pipe Financing Early2026
- $135 million oversubscribed PIPE
- Weighted Avg Shares Q2 2025
- 86238084
- Weighted Avg Shares Q2 2026
- 205778156
- Cnty813 Initial Clinical Data
- 2H 2027
- Loss On Lease Termination Q2 2026
- 11145000
- Collaboration Revenue Six Months2025
- 109164000
Price after filing
Close on the filing date to close N calendar days later (from $1.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.